netFormulary NHS
Ipswich and East Suffolk CCG
North East Essex CCG
East Suffolk and North East Essex NHS Foundation Trust
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.08.02  Expand sub section  Oral anticoagulants
 note 

MHRA: Increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome


Primary care guidance

IESCCG guidance

For primary care guidance on the use of Direct Oral Anti-Coagulants (DOACs) and warfarin in non-valvular Atrial Fibrillation please click here

 

Hospital only guidance

Management of Bleeding

Click here for IHT guidance on management of bleeding in patients taking one of the direct oral anticoagulants

Click here for IHT guidance on the management of patients undergoing invasive procedures

Warfarin
View adult BNF View SPC online View childrens BNF
Formulary
Green

Primary care guidance

Warfarin supply

Note only 0.5mg,1mg,3mg are approved for local use

There is a risk of overdose/underdose due to confusion between 0.5mg and 5mg tablets

If patients are using 5mg tablets, consideration must be given to discontinue this strength and to prescribe 1mg and 3mg tablets to make up the required dose

 

 

Hospital only guidance

Ipswich hospital

IHT (and WSH) only keep 1mg and 3mg. Patients requiring half mg doses will need 0.5mg strength prescribed and supplied in primary care following discharge

Colchester hospital

The 500microg (0.5mg) strength is available and considered a formulary medicine

 
   
Apixaban
View adult BNF View SPC online View childrens BNF
Formulary
Mixed

Traffic light information

Traffic light Details
Red Prevention of venous thromboembolism in total hip or knee replacement in adults
Green Treatment and secondary prevention of deep vein thrombosis and pulmonary embolism
Blue

Prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation with 1 or more risk factor such as

    • Prior stroke or TIA
    • ≥75yrs
    • Hypertension
    • Diabetes mellitus
    • Symptomatic heart failure
 
Link  NICE TA275: Apixaban for AF
   
Dabigatran
View adult BNF View SPC online View childrens BNF
Formulary
Mixed

Traffic light information

Traffic light Details
Red

Prevention of venous thromboembolic (VTE) events in adult patients who undergone either:

  • Elective total hip replacement (THR)
  • Total knee replacement (TKR) surgery
Green

Treatment of:

  • Deep vein thrombosis (DVT)
  • Pulmonary embolism (PE)

Prevention of

  • Recurrent DVT
  • Recurrent PE in adults
Blue

Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation with one or more of the following risk factors:

  • Previous stroke
  • transient ischemic attack
  • or systemic embolism (SEE),
  • Left ventricular ejection fraction < 40 %
  • Symptomatic heart failure
  • ≥ New York Heart Association (NYHA) Class 2
  • Age ≥ 75 years
  • Age ≥ 65 years associated with one of the following:
    • diabetes mellitus
    • coronary artery disease
    • hypertension
 
Link  NICE TA249: Dabigatran for Stroke prevention in AF
   
Edoxaban
View adult BNF View SPC online View childrens BNF
Formulary
Mixed

Traffic light information

Traffic light Details
Green Treating and preventing DVT and PE
Blue Prevention of stroke and systemic embolism with non-valvular atrial fibrillation
 
Link  NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation
   
Rivaroxaban
View adult BNF View SPC online View childrens BNF
Formulary
Mixed

MHRA:increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial after transcatheter aortic valve replacement

MHRA: Reminder that 15 mg and 20 mg tablets should be taken with food


Traffic light information

Traffic light Details
Red

Prevention of venous thromboembolism (VTE) in adult patients undergoing either:

  • Elective hip surgery
  • Knee replacement surgery.
Green

For use in acute coronary syndrom (ACS)

Treatment of

  • Deep vein thrombosis (DVT)
  • Pulmonary embolism (PE)

Prevention of recurrent

  • Deep vein thrombosis (DVT)
  • Pulmonary embolism (PE)
Blue

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more  of the following risk factors:

  • Congestive heart failure
  • Hypertension
  • Age ≥ 75 years
  • Diabetes mellitus
  • Prior stroke
  • Priortransient ischaemic attack
 
Link  NICE TA607 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
   
Acenocoumarol
View adult BNF View SPC online View childrens BNF
Formulary
Green
 
   
Phenindione
View adult BNF View SPC online View childrens BNF
Formulary
Green
 
   
02.08.02  Expand sub section  Antidotes
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Blue

For routine prescribing in primary and secondary care.   

Green

Initiated (if clinically urgent) or advised (if non-urgent) by specialist in secondary care, prescribing can be continued in primary care.   

Amber

Shared care  

Red Hospital

Hospital only  

Double Red

There should be no prescribing of these drugs  

Mixed

The traffic light of the drug is dependant on the indication. Please see individual drug entry for details  

netFormulary